A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.

NCT07052253 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma (HCC)

Interventions

DRUG: TT-00420 (tinengotinib)
DRUG: AK104
DRUG: AK112

Sponsor

Akeso

Collaborators

[object Object]